Telavancin

Mechanism

An enhanced version of vancomycin designed to be more potent against resistant bacteria. It has a dual mechanism — not only does it block cell wall synthesis like vancomycin, but it also directly damages bacterial membranes (causes depolarization). FDA-approved for complicated skin infections and hospital-acquired MRSA pneumonia.

Effects

ANTIMICROBIAL MECHANISM: Semi-synthetic lipoglycopeptide derived from vancomycin. Dual mechanism: (1) Binds D-Ala-D-Ala on peptidoglycan precursors — inhibits both transglycosylation and transpeptidation (same as vancomycin but with higher affinity due to the lipophilic decylaminoethyl side chain). (2) The hydrophobic side chain anchors in the cell membrane, disrupting membrane potential and increasing permeability. This dual mechanism (cell wall + membrane) results in concentration-dependent, rapidly bactericidal activity against Gram-positives — faster killing kinetics than vancomycin. SPECTRUM: MRSA (MIC90 0.5 μg/mL — 4-8x more potent than vancomycin), MSSA, hVISA, VISA (retains activity against vancomycin-intermediate strains — important clinical niche), streptococci, E. faecalis (vancomycin-susceptible). Reduced activity against VanA-type VRE. No Gram-negative activity. MIC BREAKPOINTS: FDA: S. aureus susceptible ≤0.25 μg/mL. No EUCAST breakpoints (limited European use). RESISTANCE: No established telavancin-specific resistance mechanism. VanA-type resistance reduces but may not abolish activity. The membrane-disrupting mechanism provides activity even when cell wall target is modified. Cross-resistance with vancomycin is incomplete. PHARMACOKINETICS: Half-life ~8 hours. High protein binding (93%). Vd ~0.13 L/kg. Renal elimination — dose adjust for CrCl <50 mL/min (important). Penetrates well into pulmonary epithelial lining fluid (ELF) — key advantage for pneumonia (concentrations in ELF are bactericidal). CLINICAL INDICATIONS: FDA-approved for (1) cSSSI (complicated skin and skin structure infections) and (2) HABP/VABP (hospital-acquired/ventilator-associated bacterial pneumonia) caused by susceptible Gram-positives, specifically when alternative agents are not suitable. The "when alternatives are not suitable" qualifier reflects FDA concerns about nephrotoxicity. TOXICITY: NEPHROTOXICITY: The primary concern. Rate varies (10-16% in RCTs). Mechanism not fully characterized. FDA requires baseline CrCl and monitoring q48-72h. BLACK BOX WARNING for fetal risk (teratogenic in animal studies — obtain pregnancy test before use in women of childbearing potential). Interferes with coagulation assays (aPTT and INR) similarly to oritavancin — artifact, not true coagulopathy. Taste disturbance (metallic/soapy taste) in ~33% — common and distinctive. Nausea, vomiting, foamy urine (due to surfactant-like properties of the molecule).

Practitioner Guide

CLINICAL PEARLS — INFECTIOUS DISEASE SPECIALIST PERSPECTIVE: DOSING: 10 mg/kg IV once daily. Infuse over 60 minutes. Renal adjustment: CrCl 30-50 mL/min: 7.5 mg/kg q24h. CrCl 10-29 mL/min: 10 mg/kg q48h. Hemodialysis: dose post-HD. NICHE CLINICAL ROLE: Telavancin occupies a specific niche: MRSA pneumonia when vancomycin or linezolid are not suitable. This is its strongest indication because of excellent ELF penetration. For MRSA HABP/VABP: telavancin achieves ELF concentrations 5-10x above MRSA MIC — better than vancomycin (which penetrates lung poorly). WHEN TO USE: (1) MRSA pneumonia with vancomycin failure or intolerance. (2) MRSA pneumonia with vancomycin MIC ≥2 (where vancomycin efficacy declines). (3) hVISA/VISA pneumonia — telavancin retains activity. (4) Complicated skin infections when alternatives are exhausted. KEY CLINICAL LIMITATION: The nephrotoxicity concern has limited adoption. In the ATTAIN trials (HABP/VABP), patients with baseline CrCl <50 had worse outcomes with telavancin vs. vancomycin. This led to the restrictive labeling ("when alternatives are not suitable"). In practice: avoid in patients with pre-existing renal impairment if possible. COAGULATION ASSAY INTERFERENCE: Same issue as oritavancin. Artificially prolongs aPTT and INR. Draw coagulation labs just before the telavancin dose (at trough, when interference is minimal). Inform lab and clinical teams. Cannot reliably monitor UFH. TASTE DISTURBANCE: ~33% of patients report metallic/soapy taste. This is the molecule acting as a surfactant on taste buds. Warn patients it is harmless and temporary. May last for the duration of therapy. FOAMY URINE: Telavancin has surfactant properties — causes urine to foam. This alarms patients. Reassure them this is an expected drug effect, not proteinuria (though check UA if concerned). MONITORING: SCr q48-72h (FDA requirement). Baseline pregnancy test for women of childbearing potential (BLACK BOX teratogenicity). CBC, CMP at baseline and periodic. No TDM needed. COMPARISON: Telavancin vs. vancomycin for MRSA pneumonia: telavancin has better lung penetration and broader MRSA activity (including hVISA/VISA) but more nephrotoxicity and coagulation assay interference. In patients with normal renal function and MRSA pneumonia not responding to vancomycin, telavancin is a rational choice.

Evidence

• A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.

  Stryjewski ME et al. (2014) — BMC Infectious Diseases — PMID: 24884578

  In a small randomized Phase II study of uncomplicated S. aureus bacteremia, telavancin showed similar clinical cure to standard therapy, including cure among MRSA cases, but had more clinically significant creatinine elevation.

  moderate

Research Summary

TIER 1 (Gold Standard): Rubinstein et al., 2011 (ATTAIN 1 & 2) — Phase III RCTs of telavancin vs. vancomycin for HABP/VABP: non-inferior overall, but worse outcomes in patients with pre-existing renal impairment (Clinical Infectious Diseases, PMID: 21507922). Stryjewski et al., 2005 (FAST) — Phase II RCT for cSSSI. Corey et al., 2008 (ATLAS 1 & 2) — Phase III RCTs for cSSSI: non-inferior to vancomycin. FDA-approved 2009 (cSSSI) and 2013 (HABP/VABP). TIER 2 (Strong): Lunde et al., 2016 — ELF penetration data (Antimicrobial Agents and Chemotherapy). Zhanel et al., 2010 — comprehensive pharmacology review (Drugs). DrugBank DB06402. IDSA MRSA guidelines mention telavancin as alternative. PK/PD models supporting once-daily dosing. TIER 3 (Moderate): Clinical experience from pulmonary and ID specialists using telavancin for refractory MRSA pneumonia. Case series for hVISA/VISA infections. Post-marketing safety data. Conference presentations at IDWeek, CHEST. KEY FINDINGS: (1) Best-in-class lung penetration among glycopeptides — ideal for MRSA pneumonia. (2) Activity against hVISA/VISA fills an important treatment gap. (3) Nephrotoxicity limits broader use. (4) Coagulation assay interference and taste disturbance are practical burdens. (5) Niche agent — not first-line, but valuable when needed. GAPS: Whether telavancin is truly superior to high-dose vancomycin for MRSA pneumonia (no direct comparison at modern vancomycin AUC targets). Role in salvage therapy for daptomycin-non-susceptible infections. Long-term safety in extended therapy. ACTIVE TRIALS: Limited ongoing trials. Post-marketing surveillance continues.